AVAVA has secured a $15 million debt facility from Catalio Capital Management as part of a broader $45 million financing package.
The package comprises the debt facility and a $30 million equity financing, with Catalio leading both. New and existing investors also participated.
AVAVA said it will use the proceeds for commercial expansion, its innovation pipeline and global growth. The company has also launched its AVAVA 2.0 software upgrade and is continuing clinical and regulatory programmes while expanding its commercial and international footprint.
AVAVA is a Boston-based medical aesthetics medtech company developing energy-based technologies using its proprietary Focal Point Technology.
Catalio was AVAVA’s first institutional investor and has remained a longstanding partner of the company. The New York-based firm invests across healthcare private, public and credit markets.
UBS Investment Bank and Oak Hill Securities advised AVAVA on the transaction.